GlassScriptPhysician profile
Sarah Williams
NPI 1205210820
$2,115.14
in general payments reported to CMS, 2019-2025
30 companies · $809 in 2025
The $809 reported for 2025 was more than what 85% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $510 · 2022: $243 · 2023: $77.90 · 2024: $475 · 2025: $809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,362.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $377.20 | 2021-2024 | Briviact |
| Astrazeneca Pharmaceuticals LP | $287.95 | 2021-2022 | |
| Abbvie INC. | $219.25 | 2021-2025 | |
| Incyte Corporation | $185.17 | 2024-2025 | Jakafi, Monjuvi, Niktimvo |
| Abbott Laboratories | $152.63 | 2022-2023 | Cardiomems |
| Janssen Biotech, INC. | $87.27 | 2024-2025 | Carvykti |
| Syndax Pharmaceuticals, INC. | $74.57 | 2025 | Revuforj |
| Legend Biotech USA INC. | $59.33 | 2025 | Carvykti |
| Blueprint Medicines Corporation | $57.81 | 2024-2025 | Ayvakit |
| Astellas Pharma US INC | $57.34 | 2025 | Cresemba |
| Abiomed | $49.77 | 2025 | |
| Genentech USA, INC. | $44.64 | 2024-2025 | Polivy, Lunsumio |
| Rigel Pharmaceuticals, INC. | $43.96 | 2024-2025 | Rezlidhia, Tavalisse, Gavreto |
| Genzyme Corporation | $43.14 | 2025 | |
| Medtronic, INC. | $37.83 | 2022-2024 | Linq II |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $36.58 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $33.22 | 2021-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $28.80 | 2025 | |
| Beigene USA, INC. | $28.25 | 2024 | Brukinsa |
| Kiniksa Pharmaceuticals International, Plc | $24.71 | 2024 | Arcalyst |
| Lilly USA, LLC | $22.58 | 2025 | Jaypirca |
| Atricure, INC. | $22.15 | 2024 | |
| Cumberland Pharmaceuticals, INC. | $20.56 | 2024 | Sancuso |
| Novo Nordisk INC | $20.34 | 2025 | Wegovy |
| Edwards Lifesciences Corporation | $19.09 | 2025 | Sapien 3 Ultra Resilia |
| Pharmaessentia USA Corporation | $18.18 | 2025 | Besremi |
| Novartis Pharmaceuticals Corporation | $17.98 | 2023 | |
| Merck Sharp & Dohme LLC | $17.59 | 2024 | Reblozyl |
| Beone Medicines USA, INC. | $14.28 | 2025 | Brukinsa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $12.97 | 2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.